Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine

NCT02849951 is registered in ClinicalTrials.gov with Prometheus Laboratories as lead sponsor.

NCT NCT02849951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02849951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine
Lead sponsor
Prometheus Laboratories
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2016
Completion date
August 31, 2019
Enrollment
25 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis